PFE | Weekly | Haru Insights

Pfizer’s FDA approval of Ibrance in HR-positive, HER2-positive breast cancer marks a transformative regulatory milestone, expanding the drug’s patient population and reinforcing its role as a cornerstone oncology asset.
The Vyndaqel patent extension to June 2031 secures U.S. exclusivity for a key high-margin product, providing critical near-term earnings stability and reducing near-term revenue risk.

The Ibrance approval is a game-changer, proving Pfizer can still deliver blockbuster innovation in oncology and reassert its leadership in high-impact therapies—a rare win in an otherwise stagnant pipeline.
The Vyndaqel patent extension is not just protective—it’s strategic, locking in decades of royalties and shielding earnings from generic erosion at a crucial time.
Metsera’s ultra-long-acting GLP-1 could reposition Pfizer as a true obesity therapeutic challenger, with potential to disrupt Eli Lilly’s dominance by 2028—a bold, underappreciated bet with massive upside.
Despite macro headwinds, Pfizer’s 7.3% dividend yield remains a fortress, and at 8.5x forward P/E, it offers steep value for income investors seeking stability amid volatility.
The combination of FDA wins, patent protection, and pipeline diversification signals that Pfizer is not merely surviving—it’s strategically repositioning for sustained relevance in a post-pandemic world.

Pfizer Inc. (PFE)[Tv]